Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones

Co-Diagnostics, Inc.

2026-Q1 EPS reported -$4.06 revenue$145,954

Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.
Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.
Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.
Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.